摘要
目的研究以替吉奥为基础联合阿帕替尼对进展期胃癌患者免疫功能及血清细胞因子水平的影响。方法选取本院89例进展期胃癌患者,采用随机数字表法分组,对常规组44例采用奥沙利铂、替吉奥治疗,对研究组45例增加阿帕替尼,对比两组患者血清肿瘤标志物水平、血清细胞因子水平、免疫功能和不良反应。结果研究组治疗后癌胚抗原(CEA)、糖类抗原125(CA125)水平低于常规组(P<0.05);研究组治疗后血清γ-干扰素(IFN-γ)、正常上皮细胞特异性-1基因(NES1)、白介素-10(IL-10)和肿瘤坏死因子-α(TNF-α)水平高于常规组(P<0.05);研究组治疗后T淋巴细胞(CD8+)水平低于常规组,CD3+、CD4+水平高于常规组(P<0.05)。结论以替吉奥为基础联合阿帕替尼三药方案对进展期胃癌患者效果确切,能够有效提高患者的免疫功能,改善血清细胞因子水平,降低血清肿瘤标志物水平,安全性高。
Objective To study the effects of Tegafur-based Three-Drug Regimen combined Apatinib on immune function and serum cytokine levels in patients with advanced gastric cancer.Methods A total of 89 patients with advanced gastric cancer in our hospital were divided by random number table method.44 patients in the conventional group were treated with Oxaliplatin and Tegafur,and 45 patients in the study group were treated with Apatinib.Serum tumor marker levels,serum cytokine levels,immune function and adverse reactions were compared between the two groups.Results The levels of carcinoembryonic antigen(CEA)and carbohydrate antigen 125(CA125)in the study group were lower than those in the conventional group(P<0.05).After treatment,the serum levels ofγ-interferon(IFN-γ),normal epithelial cell specific-1 gene(NES1),interleukin-10(IL-10)and tumor necrosis factor-α(TNF-α)in the study group were higher than those in the conventional group(P<0.05).The level of T lymphocytes(CD8+)in the study group was lower than that in the conventional group after treatment,and the levels of CD3+and CD4+were higher than those in the conventional group(P<0.05).Conclusion The three-drug regimen based on Tegafur combined with Apatinib can effectively improve the immune function of patients with advanced gastric cancer,improve the level of serum cytokines,and reduce the level of serum tumor markers,with high safety.
作者
林志明
杨柳
杨旭初
LIN Zhiming;YANG Liu;YANG Xuchu(Department of Hematology and Oncology(Geriatrics),Shangshui County People’s Hospital,Shangshui,Henan 466100,China;Department of Pharmacy,Shangshui People’s Hospital,Shangshui,Henan 466100,China;Department of Oncology,Henan Cancer Hospital,Zhengzhou,Henan 450000,China)
出处
《生物医学工程学进展》
CAS
2024年第3期275-280,共6页
Progress in Biomedical Engineering
